NNNN חוב כולל להון Anbio

Anbio Biotechnology (NNNN) is attracting leading molecular experts and biochemists to develop its R&D center, maintaining a stable workforce. The business relies on global shipments of diagnostic systems to clinics of various scales, which minimizes regional risks. The debt-to-equity ratio stands at 0.00, complementing this price chart illustrating valuation trends and confirming the developer's status as a provider of affordable AI analyzers for rapid diagnostics.

Amidst fierce competition in the IVD diagnostics sector, Anbio Biotechnology (NNNN) requires a balance between R&D investments and financial stability. This indicator measures the proportion of borrowed funds relative to equity, determining the business's level of dependence on creditors and the risk of default. By analyzing the company's debt-to-equity ratio, an investor can assess whether excessive conservatism is limiting the company's expansion pace.